Cargando…

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas

Pleomorphic dermal sarcomas (PDS) are rare neoplasms of the skin that occur in UV-exposed sites in the elderly, but represent the most common cutaneous sarcomas. Although the majority of PDS can be surgically removed, local recurrences occur in up to 28%, usually occurring within the first two years...

Descripción completa

Detalles Bibliográficos
Autores principales: Helbig, Doris, Klein, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712951/
https://www.ncbi.nlm.nih.gov/pubmed/36465341
http://dx.doi.org/10.3389/fonc.2022.975342
_version_ 1784841898662297600
author Helbig, Doris
Klein, Sebastian
author_facet Helbig, Doris
Klein, Sebastian
author_sort Helbig, Doris
collection PubMed
description Pleomorphic dermal sarcomas (PDS) are rare neoplasms of the skin that occur in UV-exposed sites in the elderly, but represent the most common cutaneous sarcomas. Although the majority of PDS can be surgically removed, local recurrences occur in up to 28%, usually occurring within the first two years after primary excision. Metastases are diagnosed in up to 20% of cases, mainly observed in the skin, lymph nodes and lungs, preferentially affecting patients with underlying hemato-oncologic diseases. Similar to other UV-induced tumors, PDS are inflammatory and immunogenic tumors (with a high number of CD4+/CD8+ tumor-infiltrating lymphocytes (TILs) and checkpoint molecule expression such as PD-L1, LAG-3, TIGIT) with a very high mutational burden. The most common genetic alterations include UV-induced TP53 loss of function mutations, followed by alterations in the CDKN2A/B gene. Rarely, targetable genetic alterations can be detected. Compelling experimental data and clinical reports about PD-1/PD-L1-blocking antibodies in patients with PDS suggest its use as first line treatment in unresectable or metastatic tumor stages. However, individual („off-line”) patient management should be discussed in an interdisciplinary tumor board based on molecular genetic testing, mutational burden, PD-L1 expression, and evidence of tumor-infiltrating lymphocytes in addition to comorbities of the individual patient.
format Online
Article
Text
id pubmed-9712951
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97129512022-12-02 Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas Helbig, Doris Klein, Sebastian Front Oncol Oncology Pleomorphic dermal sarcomas (PDS) are rare neoplasms of the skin that occur in UV-exposed sites in the elderly, but represent the most common cutaneous sarcomas. Although the majority of PDS can be surgically removed, local recurrences occur in up to 28%, usually occurring within the first two years after primary excision. Metastases are diagnosed in up to 20% of cases, mainly observed in the skin, lymph nodes and lungs, preferentially affecting patients with underlying hemato-oncologic diseases. Similar to other UV-induced tumors, PDS are inflammatory and immunogenic tumors (with a high number of CD4+/CD8+ tumor-infiltrating lymphocytes (TILs) and checkpoint molecule expression such as PD-L1, LAG-3, TIGIT) with a very high mutational burden. The most common genetic alterations include UV-induced TP53 loss of function mutations, followed by alterations in the CDKN2A/B gene. Rarely, targetable genetic alterations can be detected. Compelling experimental data and clinical reports about PD-1/PD-L1-blocking antibodies in patients with PDS suggest its use as first line treatment in unresectable or metastatic tumor stages. However, individual („off-line”) patient management should be discussed in an interdisciplinary tumor board based on molecular genetic testing, mutational burden, PD-L1 expression, and evidence of tumor-infiltrating lymphocytes in addition to comorbities of the individual patient. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9712951/ /pubmed/36465341 http://dx.doi.org/10.3389/fonc.2022.975342 Text en Copyright © 2022 Helbig and Klein https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Helbig, Doris
Klein, Sebastian
Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
title Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
title_full Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
title_fullStr Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
title_full_unstemmed Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
title_short Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
title_sort immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712951/
https://www.ncbi.nlm.nih.gov/pubmed/36465341
http://dx.doi.org/10.3389/fonc.2022.975342
work_keys_str_mv AT helbigdoris immunecheckpointinhibitorsforunresectableormetastaticpleomorphicdermalsarcomas
AT kleinsebastian immunecheckpointinhibitorsforunresectableormetastaticpleomorphicdermalsarcomas